Mesoblast (ASX:MSB) Insider Eric Rose Sells 638,670 Shares

Mesoblast Limited (ASX:MSB) insider Eric Rose sold 638,670 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of A$2.97, for a total value of A$1,894,295.22.

Eric Rose also recently made the following trade(s):

• On Friday, January 9th, Eric Rose purchased 1,280,651 shares of Mesoblast stock. The shares were bought at an average price of A$0.01 per share, for a total transaction of A$12,806.51.

Mesoblast Stock Performance

The company has a current ratio of 1.18, a quick ratio of 1.82 and a debt-to-equity ratio of 24.76. The firm has a market cap of $2.32 billion, a P/E ratio of -23.29, a price-to-earnings-growth ratio of 9.56 and a beta of 2.38.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.